Barclays’s Gyre Therapeutics GYRE Stock Holding History
Bought
Maintained
Sold
Other funds holding GYRE
Barclays's GYRE Position: Q3 2026 in Review
Barclays increased its Gyre Therapeutics (GYRE) stake by 922% in Q3 2026, buying an estimated $198K and bringing the position to 32,975 shares worth $242K. The position accounts for ﹤0.01% of the portfolio, ranked #3851.
Barclays first reported a position in GYRE in Q2 2013 and has held it in 42 quarters since. The position peaked at $454K in Q2 2018. 58 funds tracked by Wall St. Rank hold GYRE as of Q3 2026.
- Barclays held 32,975 shares of Gyre Therapeutics worth $242K as of Q3 2026.
- Barclays bought 29,747 Gyre Therapeutics shares in Q3 2026, an estimated $198K.
- Gyre Therapeutics made up ﹤0.01% of Barclays's portfolio in Q3 2026, its #3851 holding.
- Barclays first reported a position in Gyre Therapeutics in Q2 2013 and has held it in 42 quarters since.
- Barclays's Gyre Therapeutics position peaked at $454K in Q2 2018.
- 58 funds tracked by Wall St. Rank held Gyre Therapeutics as of Q3 2026.
Based on Barclays's 13F filing for Q3 2026, filed 6 Nov 2026.